Lucas A Chibli1, Annylory L Rosa1, Maria Cristina Nonato2, Fernando B Da Costa3. 1. AsterBioChem Research Team, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Ribeirão Preto, SP, 14040-903, Brazil. 2. Laboratory of Protein Crystallography, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Ribeirão Preto, SP, 14040-903, Brazil. 3. AsterBioChem Research Team, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Ribeirão Preto, SP, 14040-903, Brazil. febcosta@fcfrp.usp.br.
Abstract
INTRODUCTION: Interesting data about the family Asteraceae as a new source of Leishmania major dihydroorotate dehydrogenase (LmDHODH) inhibitors are presented. This key macromolecular target for parasites causing neglected diseases catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which takes part in major cell functions, including DNA and RNA biosynthesis. OBJECTIVES: We aimed to (1) determine LmDHODH inhibitor candidates, revealing the type of chemistry underlying such bioactivity, and (2) predict the inhibitory potential of extracts from new untested plant species, classifying them as active or inactive based on their LC-MS based metabolic fingerprints. METHODS: Extracts from 150 species were screened for the inhibition of LmDHODH, and untargeted UHPLC-(ESI)-HRMS metabolomic studies were carried out in combination with in silico approaches. RESULTS: The IC50 values determined for a subset of 59 species ranged from 148 µg mL-1 to 9.4 mg mL-1. Dereplication of the metabolic fingerprints allowed the identification of 48 metabolites. A reliable OPLS-DA model (R2 > 0.9, Q2 > 0.7, RMSECV < 0.3) indicated the inhibitor candidates; nine of these metabolites were identified using data from isolated chemical standards, one of which-4,5-di-O-E-caffeoylquinic acid (IC50 73 µM)-was capable of inhibiting LmDHODH. The predictive OPLS model was also effective, with 60% correct predictions for the test set. CONCLUSION: Our approach was validated for (1) the discovery of LmDHODH inhibitors or interesting starting points for the optimization of new leishmanicides from Asteraceae species and (2) the prediction of extracts from untested species, classifying them as active or inactive.
INTRODUCTION: Interesting data about the family Asteraceae as a new source of Leishmania major dihydroorotate dehydrogenase (LmDHODH) inhibitors are presented. This key macromolecular target for parasites causing neglected diseases catalyzes the fourth reaction of the de novo pyrimidine biosynthetic pathway, which takes part in major cell functions, including DNA and RNA biosynthesis. OBJECTIVES: We aimed to (1) determine LmDHODH inhibitor candidates, revealing the type of chemistry underlying such bioactivity, and (2) predict the inhibitory potential of extracts from new untested plant species, classifying them as active or inactive based on their LC-MS based metabolic fingerprints. METHODS: Extracts from 150 species were screened for the inhibition of LmDHODH, and untargeted UHPLC-(ESI)-HRMS metabolomic studies were carried out in combination with in silico approaches. RESULTS: The IC50 values determined for a subset of 59 species ranged from 148 µg mL-1 to 9.4 mg mL-1. Dereplication of the metabolic fingerprints allowed the identification of 48 metabolites. A reliable OPLS-DA model (R2 > 0.9, Q2 > 0.7, RMSECV < 0.3) indicated the inhibitor candidates; nine of these metabolites were identified using data from isolated chemical standards, one of which-4,5-di-O-E-caffeoylquinic acid (IC50 73 µM)-was capable of inhibiting LmDHODH. The predictive OPLS model was also effective, with 60% correct predictions for the test set. CONCLUSION: Our approach was validated for (1) the discovery of LmDHODH inhibitors or interesting starting points for the optimization of new leishmanicides from Asteraceae species and (2) the prediction of extracts from untested species, classifying them as active or inactive.
Authors: Amal M M Nour; Sami A Khalid; Marcel Kaiser; Reto Brun; Wai'I E Abdalla; Thomas J Schmidt Journal: J Ethnopharmacol Date: 2010-02-26 Impact factor: 4.360
Authors: Gabriel Alfonso Gutiérrez-Rebolledo; Susan Drier-Jonas; María Adelina Jiménez-Arellanes Journal: Asian Pac J Trop Med Date: 2017-11-07 Impact factor: 1.226
Authors: Rafael Alberto Martínez-Díaz; Alexandra Ibáñez-Escribano; Jesús Burillo; Lorena de Las Heras; Gema Del Prado; M Teresa Agulló-Ortuño; Luis F Julio; Azucena González-Coloma Journal: Mem Inst Oswaldo Cruz Date: 2015-06-24 Impact factor: 2.743
Authors: Mihály Sulyok; Thomas Rückle; Alexandra Roth; Raymund E Mürbeth; Stephan Chalon; Nicola Kerr; Sonia Schnieper Samec; Nathalie Gobeau; Carlos Lamsfus Calle; Javier Ibáñez; Zita Sulyok; Jana Held; Tamirat Gebru; Patricia Granados; Sina Brückner; Christian Nguetse; Juliana Mengue; Albert Lalremruata; B Kim Lee Sim; Stephen L Hoffman; Jörg J Möhrle; Peter G Kremsner; Benjamin Mordmüller Journal: Lancet Infect Dis Date: 2017-03-28 Impact factor: 25.071
Authors: Philippe Rocca-Serra; Reza M Salek; Masanori Arita; Elon Correa; Saravanan Dayalan; Alejandra Gonzalez-Beltran; Tim Ebbels; Royston Goodacre; Janna Hastings; Kenneth Haug; Albert Koulman; Macha Nikolski; Matej Oresic; Susanna-Assunta Sansone; Daniel Schober; James Smith; Christoph Steinbeck; Mark R Viant; Steffen Neumann Journal: Metabolomics Date: 2015-11-17 Impact factor: 4.290
Authors: Alvaro Luis Lamas Cassago; Mateus Manfrin Artêncio; Janaina de Moura Engracia Giraldi; Fernando Batista Da Costa Journal: Eur Food Res Technol Date: 2021-06-15 Impact factor: 2.998